- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:18 | Impact Biomedical announces 3F US patent issue | 1 | Seeking Alpha | ||
| 14:36 | Impact Biomedical Inc (IBO) Announces 3F US Patent Issue | 78 | GlobeNewswire (Europe) | HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBO) is pleased to announce that the US Patent and Trademark Office has issued U.S. patent No. 12,357,584 B2 entitled "Composition... ► Artikel lesen | |
| IMPACT BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| Do | IMPACT BIOMEDICAL INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 24.06. | DSS, Inc.'s Subsidiary, Impact BioMedical Inc., Announces Strategic Merger | 154 | GlobeNewswire (Europe) | NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) ("DSS" or the "Company"), a multinational company operating across diverse industries including packaging, wealth management... ► Artikel lesen | |
| 23.06. | Impact Biomedical-Aktie steigt nach Fusionsvereinbarung mit Dr Ashleys | 11 | Investing.com Deutsch | ||
| 23.06. | Impact Biomedical stock soars after merger deal with Dr Ashleys | 1 | Investing.com | ||
| 23.06. | IMPACT BIOMEDICAL INC; Dr Ashleys Limited: Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger | 282 | GlobeNewswire (Europe) | A Strategic Move to Accelerate Market Reach for Innovative Pharmaceutical Patents on June 23, 2025 NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Dr Ashleys Limited, a Hong Kong based global pharmaceutical... ► Artikel lesen | |
| 23.06. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.03. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 21.03. | Impact BioMedical-Aktien steigen bei unerklärlicher Marktaktivität | 8 | Investing.com Deutsch | ||
| 21.03. | Impact BioMedical shares soar on unexplained market activity | 1 | Investing.com | ||
| 21.03. | Impact BioMedical-Aktie schwankt ohne erkennbaren Grund | - | Investing.com Deutsch | ||
| 21.03. | Impact BioMedical shares fluctuate without clear cause | 1 | Investing.com | ||
| 21.03. | Impact Biomedical Inc. Announcement Stock Activity/Pricing | 261 | GlobeNewswire (Europe) | HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare... ► Artikel lesen | |
| 21.03. | Pre-market Movers: Allurion Technologies, Impact BioMedical, Patriot National Bancorp, TransCode Therapeutics, DSS, Inc. | 720 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.10 A.M. ET).In the Green Allurion Technologies Inc. (ALUR) is up over 64% at... ► Artikel lesen | |
| 21.03. | Why Impact Biomedical Inc. (IBO) Surged On Thursday? | 16 | Insider Monkey | ||
| 13.03. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | 5 | SEC Filings | ||
| 26.02. | Impact BioMedical acquires air purifier firm Celios | 2 | Investing.com | ||
| 26.02. | DSS, Inc. Announces Sale of Celios to Impact BioMedical, Streamlining Portfolio for Strategic Growth | 342 | GlobeNewswire (Europe) | ROCHESTER, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company focused on innovation-driven business models, today announced the sale of its Celios® air... ► Artikel lesen | |
| 26.02. | Impact Biomedical Inc. Announces Acquisition of Celios, "Protecting People, Plants, and Animals from the World's Most Dangerous Pathogens With Clean-Room Air Quality" | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 42,160 | +0,48 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Qiagen nach Zahlen von 54 auf 57 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Tycho Peterson attestierte dem... ► Artikel lesen | |
| PROPANC BIOPHARMA | 6,360 | +112,00 % | Stocks Moving Premarket: PPCB, BTAI, Tonix Pharmaceuticals, DAY, TPIC, And Other Gainers & Losers | OTTAWA (dpa-AFX) - At 6.50 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| EVOTEC | 6,318 | -0,60 % | Evotec-Aktie: Kurs heute im Minus (6,566 €) | Die Evotec-Aktie notiert heute etwas leichter. Das Papier kostete zuletzt 6,57 Euro. Heute hat sich an der deutschen Börse die Aktie von Evotec zwischenzeitlich um 3,13 Prozent verbilligt. Der Kurs... ► Artikel lesen | |
| VALNEVA | 5,140 | +7,85 % | Valneva: Operativer Cashburn deutlich verringert - Umsatz steigt | Valneva hat im ersten Halbjahr 2025 die Gesamterlöse um 37,8 Prozent auf 97,6 Millionen Euro gesteigert. Der Umsatz aus Produktverkäufen stieg um 33,3 Prozent auf 91 Millionen Euro. Das Unternehmen... ► Artikel lesen | |
| TEMPUS AI | 67,00 | +5,51 % | Tempus AI: KI-Aktie wie entfesselt nach Zahlen | Der KI-Spezialist Tempus AI hat vor wenigen Handelstagen einen überzeugenden Bericht zum zweiten Quartal vorgelegt. Seitdem kennt die Aktie des Unternehmens, welches erst vor rund zehn Jahren in Chicago... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 26,510 | -0,67 % | Summit Therapeutics: Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025 | Ivonescimab to be Featured at WCLC Presidential Symposium for Second Consecutive Year
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the... ► Artikel lesen | |
| BIONTECH | 96,95 | -0,10 % | BioNTech Aktie: Unterwegs zur großen Trendwende? | Die BioNTech Aktie befindet sich seit dem Jahrestief 2025 vom 7. April bei 81,20 Dollar in einem sekundären Aufwärtstrend. Trotz dieser Erholung blieb die Dynamik in den vergangenen Wochen verhalten... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,575 | -3,30 % | Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid | ||
| BEAM THERAPEUTICS | 17,690 | -0,67 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 44,850 | -3,65 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| Y-MABS THERAPEUTICS | 8,525 | 0,00 % | Y-mAbs Therapeutics, Inc.: Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments | Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company's guidance range of between $17 million and $19 millionSERB Pharmaceuticals to acquire... ► Artikel lesen | |
| LENZ THERAPEUTICS | 38,670 | +2,11 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 16,740 | -0,95 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,710 | +4,24 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| ITEOS THERAPEUTICS | 10,115 | +0,10 % | iTeos Therapeutics Inc.: iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right | WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement... ► Artikel lesen |
IMPACT BIOMEDICAL INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,032 (+5,66 %) liegt der Kurs bei 0,595 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMPACT BIOMEDICAL INC finden Sie auf Wallstreet Online.